Interestingly, MYCN showed high-level focal amplifications in a subset of GBM samples (51), and MYC or MYCN is found to be amplified in almost half of brain cancers that have combined features of malignant glioma and primitive neuroectodermal tumors (MG-PNET) (15). This evidence concerns the gene MYCN and glioblastoma.